Creative Commons source reading · Parkinson’s disease and related disorders
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
Klaus Seppi; K Ray Chaudhuri; Miguel Coelho; Susan H Fox; Regina Katzenschlager; Santiago Perez Lloret; Daniel Weintraub; Cristina Sampaio; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee
Originally published in Movement disorders : official journal of the Movement Disorder Society · 2019-01-17
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Objective To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD). Background The International Parkinson and Movement Disorder Society Evidence-Based Medicine Committee's recommendations for treatments of PD were first published in 2002, updated in 2011, and now updated again through December 31, 2016. Methods Level I studies testing pharmacological, surgical, or nonpharmacological interventions for the treatment of nonmotor symptoms in PD were reviewed. Criteria for inclusion and quality scoring were as previously reported. The disorders covered were a range of neuropsychiatric symptoms, autonomic dysfunction, disorders of sleep and wakefulness, pain, fatigue, impaired olfaction, and ophthalmologic dysfunction. Clinical efficacy, implications for clinical practice, and safety conclusions are reported. Results A total of 37 new studies qualified for review. There were no randomized controlled trials that met inclusion criteria for the treatment of anxiety disorders, rapid eye movement sleep behavior disorder, excessive sweating, impaired olfaction, or ophthalmologic dysfunction.
Methods
The previous MDS EBM reviews on treatments for NMS of PD reviewed studies from January 2004 to December 2010. We have continued the process and included new studies published up to December 31, 2016. If new interventions not reviewed in prior EBM publications were identified, further searches were made retrospectively to include all appropriate studies.3
Results and Conclusions
There were no RCTs that met inclusion criteria for the treatment of anxiety disorders, rapid eye movement (REM) sleep behavior disorder (RBD), excessive sweating, or olfactory or ophthalmologic dysfunction.
Discussion
The present EBM review summarizes the best available evidence from RCTs published from January 2011 to December 2016. Although we have identified a number of efficacious treatments, for many interventions there is insufficient evidence to make adequate conclusions on their efficacy. Indeed, for several indications further RCTs are required. Safety profiles of most of the interventions reviewed in this update are largely based on studies performed in non‐PD populations without firm evidence of efficacy from RCTs in PD.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
